Abstract：
After more than a decade of good results using the combination of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinosis of colorectal origin, the PRODIGE7 study, which specifically evaluated the role of HIPEC, failed to show any superiority in terms of overall and disease-free survival for the CRS+HIPEC combination compared with CRS alone. This study constituted a radical change in the knowledge and therapeutic attitudes observed to date. After reviewing the literature and the consensus of national and international experts, a synthesis is provided, together with an outlook on the questions raised and the therapeutic trials and innovations of the near future. An analysis of recent advances due to the advent of a new technique, PIPAC, is also proposed, as well as a review of current therapeutic trials in this field.
摘要：
经过十多年的良好结果，使用细胞减灭术（CRS）加腹腔热化疗（HIPEC）联合治疗结直肠起源的腹膜癌，PRODIGE7研究,专门评估了HIPEC的作用，与单独使用CRS相比,CRS+HIPEC组合在总体生存率和无病生存率方面未能显示出任何优势.这项研究构成了迄今为止观察到的知识和治疗态度的根本变化。在查阅文献和国内外专家的共识后，提供了一种合成，以及对提出的问题以及不久的将来的治疗试验和创新的展望。分析了由于新技术的出现而取得的最新进展，PIPAC,还提议，以及对该领域当前治疗试验的回顾。
